# OnCo record paediatric-high-grade-glioma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/paediatric-high-grade-glioma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "paediatric-high-grade-glioma" ;
  schema:name "Paediatric high-grade glioma (excluding diffuse midline glioma)"@en ;
  schema:alternateName "pHGG"@en, "Childhood high-grade glioma"@en, "Paediatric glioblastoma"@en, "Diffuse hemispheric glioma, H3 G34-mutant"@en, "Infant-type hemispheric glioma"@en ;
  schema:description "High-grade gliomas in children look like adult glioblastoma under the microscope but are driven by different genes, so they are now classified separately. Surgery and radiotherapy remain the mainstay and chemotherapy adds little; the real gains are in small subsets with a targetable gene change, such as BRAF V600E tumours and the fusion-driven tumours of infants."@en ;
  schema:url <https://onco.cc/cancers/paediatric-high-grade-glioma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Glioma> ;
  schema:citation <https://en.wikipedia.org/wiki/Glioma>, <https://www.cancer.gov/types/brain/hp/child-astrocytoma-treament-pdq> ;
  onco:tag "subtype-page", "cns", "paediatric" ;
  onco:related <https://onco.cc/cancers/dipg-dmg/>, <https://onco.cc/cancers/paediatric-low-grade-glioma/>, <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/brain-tumours/>, <https://onco.cc/cancers/childhood-cancers/> ;
  onco:technologies <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/glioma-car-t/> ;
  onco:targets <https://onco.cc/targets/braf/>, <https://onco.cc/targets/mek/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/lorlatinib/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/institutions/siop-europe/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/glioma-signalling/> ;
  onco:terms <https://onco.cc/terms/h3k27m/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/re-irradiation/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:pipeline <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/technologies/glioma-car-t/>, <https://onco.cc/technologies/bbb-focused-ultrasound/>, <https://onco.cc/technologies/methylation-profiling/> ;
  onco:standardOfCare <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/re-irradiation/>, <https://onco.cc/technologies/glioma-car-t/> .